scholarly article | Q13442814 |
P50 | author | Raúl Rabadán | Q7296181 |
Riccardo Dalla-Favera | Q30119384 | ||
Laura Pasqualucci | Q30303485 | ||
Gianluca Gaidano | Q30303486 | ||
Silvia Rasi | Q30303488 | ||
Francesco Forconi | Q30303490 | ||
Valeria Spina | Q30303495 | ||
Valter Gattei | Q30303512 | ||
Francesca Maria Rossi | Q64785039 | ||
Robin Foà | Q66385416 | ||
Pietro Bulian | Q87269929 | ||
Davide Rossi | Q89878155 | ||
Alessio Bruscaggin | Q114336632 | ||
Carmela Ciardullo | Q114336633 | ||
Clara Deambrogi | Q114336634 | ||
Roberto Marasca | Q38326950 | ||
Francesco Bertoni | Q40033742 | ||
Michele Dal Bo | Q42703041 | ||
Josep Nomdedeu | Q50238034 | ||
Hossein Khiabanian | Q55167918 | ||
Giovanni Del Poeta | Q56950902 | ||
P2093 | author name string | Luca Laurenti | |
Sara Monti | |||
Roberto Serra | |||
P2860 | cites work | Detectable clonal mosaicism and its relationship to aging and cancer | Q23916196 |
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 | ||
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up | Q27851444 | ||
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation | Q27851655 | ||
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia | Q27851685 | ||
Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia | Q28255147 | ||
Detectable clonal mosaicism from birth to old age and its relationship to cancer | Q28385149 | ||
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness | Q29013141 | ||
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia | Q29614659 | ||
Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. | Q33638819 | ||
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival | Q80709731 | ||
Chronic lymphocytic leukaemia | Q80932425 | ||
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping | Q81099032 | ||
Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients | Q84537035 | ||
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia | Q34093678 | ||
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia | Q34402999 | ||
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia | Q35143490 | ||
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia | Q35220403 | ||
NOTCH1 mutations in CLL associated with trisomy 12. | Q35669190 | ||
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL | Q35794466 | ||
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia | Q36135185 | ||
Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia | Q36421804 | ||
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia | Q36462375 | ||
Tree-structured prediction for censored survival data and the Cox model | Q36701892 | ||
Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34 | Q36790673 | ||
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia | Q36843780 | ||
Risk categories and refractory CLL in the era of chemoimmunotherapy | Q37141887 | ||
Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management | Q37552813 | ||
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia | Q37980658 | ||
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns | Q39564847 | ||
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. | Q51609722 | ||
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. | Q52621343 | ||
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. | Q53596463 | ||
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. | Q55035699 | ||
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL | Q58041997 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cell biology | Q7141 |
leukemia | Q29496 | ||
lymphocyte | Q715347 | ||
chronic lymphocytic leukemia | Q1088156 | ||
P304 | page(s) | 1403-12 | |
P577 | publication date | 2013-02-21 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | |
P478 | volume | 121 |
Q90262439 | "Immuno-flowFISH" for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia |
Q58041694 | 14q deletions are associated with trisomy 12,NOTCH1mutations and unmutatedIGHVgenes in chronic lymphocytic leukemia and small lymphocytic lymphoma |
Q39266295 | 2016 WHO Classification update-What's new in lymphoid neoplasms |
Q50784932 | A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. |
Q35859176 | A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. |
Q35984259 | A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia |
Q58041425 | A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia |
Q90466691 | A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia |
Q52897018 | A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. |
Q30768193 | ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. |
Q38798801 | Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas |
Q64246205 | Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience |
Q33709543 | An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness |
Q31096565 | An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data |
Q48736600 | Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI). |
Q89823528 | B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making |
Q38185363 | B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies |
Q89090793 | B-cell receptor stereotypy and chronic lymphocytic leukaemia |
Q36825397 | BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients |
Q33409149 | Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. |
Q51587472 | Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion. |
Q40784167 | CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. |
Q33862792 | Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks |
Q30685440 | Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data |
Q50562319 | Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. |
Q37615541 | Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia |
Q26775986 | Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist |
Q56270980 | Chronic lymphocytic leukaemia |
Q39263974 | Chronic lymphocytic leukaemia genomics and the precision medicine era. |
Q91666607 | Chronic lymphocytic leukaemia: from genetics to treatment |
Q38675358 | Chronic lymphocytic leukemia (CLL)-Then and now. |
Q57034197 | Chronic lymphocytic leukemia treatment algorithm 2018 |
Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
Q38708220 | Chronic lymphocytic leukemia: Time to go past genomics? |
Q26752467 | Chronic lymphocytic leukemia: a clinical review including Korean cohorts |
Q36998431 | Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics |
Q38663689 | Clinical Impact of the 2016 Update to the WHO Lymphoma Classification |
Q38744632 | Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia |
Q42711622 | Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia |
Q37618663 | Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia? |
Q27027493 | Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond |
Q33595764 | Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia |
Q48326934 | Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. |
Q26830955 | Clinical implications of the molecular genetics of chronic lymphocytic leukemia |
Q89518987 | Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial |
Q36420752 | Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia |
Q98733440 | Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features |
Q54731667 | Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance. |
Q38262761 | Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression |
Q27027655 | Clonal evolution in hematological malignancies and therapeutic implications |
Q42330187 | Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones |
Q42291852 | Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia |
Q85738481 | CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL) |
Q85733304 | De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia |
Q26823586 | Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution |
Q35407650 | Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia |
Q34418874 | Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia |
Q92158068 | Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations |
Q91212018 | Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors |
Q33774491 | Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood |
Q33804706 | Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia |
Q92964830 | Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia |
Q37699259 | Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia |
Q40455172 | EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. |
Q39039713 | Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy |
Q93081398 | Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12 |
Q58585095 | Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials |
Q38232481 | Evolving understanding of the CLL genome |
Q33364071 | Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. |
Q37260520 | Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations |
Q50621489 | FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. |
Q64092443 | First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013 |
Q90427376 | Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature |
Q35741703 | Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans |
Q48307279 | Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia |
Q48503863 | Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients. |
Q38819164 | Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets |
Q33744997 | Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go |
Q38669131 | Genetic landscape and deregulated pathways in B-cell lymphoid malignancies |
Q37697850 | Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness |
Q37649648 | Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients |
Q28087672 | Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia |
Q52714558 | Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chornobyl cleanup workers. |
Q46444068 | High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications |
Q54348577 | How I treat patients with relapsed chronic lymphocytic leukaemia. |
Q37417412 | Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia |
Q38920650 | Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells |
Q50639003 | IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. |
Q89663745 | IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling |
Q38115229 | IX. Chronic lymphocytic leukaemia: new genetic markers as prognostic factors |
Q33424543 | Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia |
Q41485437 | Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. |
Q53147192 | IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events. |
Q49864609 | Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia |
Q61799313 | Immunochemotherapy for Richter syndrome: current insights |
Q28655983 | Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols |
Q33904307 | Increased oxidative damage associated with unfavorable cytogenetic subgroups in chronic lymphocytic leukemia. |
Q42923891 | Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? |
Q28067817 | Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies |
Q48138435 | Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. |
Q34997508 | Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia |
Q55644886 | Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. |
Q36884141 | Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease |
Q87141220 | MYC network mutations in high-risk chronic lymphocytic leukaemia |
Q92740078 | Machine learning can identify newly diagnosed patients with CLL at high risk of infection |
Q52675362 | Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. |
Q49692075 | Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia |
Q90292627 | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal? |
Q33913537 | Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups |
Q93349257 | Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications |
Q86483631 | Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis |
Q38424403 | Molecular deregulation of signaling in lymphoid tumors |
Q93603004 | Monoclonal B-cell lymphocytosis |
Q88633752 | Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review |
Q61772114 | Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group |
Q39714436 | Mutations driving CLL and their evolution in progression and relapse |
Q38724344 | Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22. |
Q64077384 | Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia |
Q55668973 | NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. |
Q47945189 | NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways. |
Q52931736 | NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. |
Q54345184 | NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. |
Q52648282 | NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. |
Q64271736 | NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia |
Q51093052 | NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. |
Q47616548 | Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis |
Q37747984 | Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. |
Q42378526 | Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. |
Q55453510 | Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients. |
Q33416524 | Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia |
Q60146450 | On statistical modeling of sequencing noise in high depth data to assess tumor evolution |
Q86703719 | On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort |
Q47582687 | Optimizing frontline therapy of CLL based on clinical and biological factors. |
Q38259446 | Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. |
Q37410709 | Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment |
Q92413642 | Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty |
Q50852727 | Predicting time to first treatment in early stage CLL: scores, values and comparative prognostic models. |
Q33714743 | Predicting treatment outcomes in CLL. |
Q38997367 | Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia |
Q47374141 | Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal |
Q38691341 | Prognostic Factors for Chronic Lymphocytic Leukemia |
Q87856666 | Prognostic Factors in the Era of Targeted Therapies in CLL |
Q38680890 | Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? |
Q38088354 | Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? |
Q89637413 | Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group |
Q96604441 | Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis |
Q42962523 | Prognostic relevance of MYD88 mutations in CLL: the jury is still out. |
Q92169106 | Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations |
Q30240258 | Prognostication of chronic lymphocytic leukemia in the era of new agents |
Q49788400 | Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation |
Q46318389 | Recent therapeutic advances in chronic lymphocytic leukemia |
Q27853022 | Recurrent mutations refine prognosis in chronic lymphocytic leukemia. |
Q47661367 | Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile |
Q50025029 | Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in no |
Q42378392 | SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis |
Q52644149 | SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. |
Q27852162 | SF3B1 mutations in chronic lymphocytic leukemia |
Q33649977 | Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China |
Q38289057 | Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy |
Q38187632 | Splicing factor mutations and cancer |
Q59797087 | TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics |
Q38177771 | TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia |
Q61803940 | Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia |
Q35146301 | Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting |
Q36920426 | The 2016 revision of the World Health Organization classification of lymphoid neoplasms |
Q37035832 | The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. |
Q37130881 | The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience |
Q55077967 | The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index |
Q36715896 | The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection |
Q52671466 | The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability. |
Q38826234 | The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. |
Q47161072 | The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). |
Q42711562 | The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. |
Q26749214 | The clinical implications of gene mutations in chronic lymphocytic leukaemia |
Q38286344 | The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications |
Q34710882 | The genomic landscape of chronic lymphocytic leukemia: clinical implications |
Q44290485 | The impact of SF3B1 mutations in CLL on the DNA-damage response |
Q36800105 | The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years |
Q38748645 | The molecular pathogenesis of chronic lymphocytic leukaemia |
Q49989104 | The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment |
Q26865760 | The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy |
Q30395427 | The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. |
Q38132818 | Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need. |
Q34453174 | Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia |
Q42427620 | UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? |
Q34016413 | Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia |
Q88195212 | Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab |
Q33817641 | Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia |
Q88739450 | [Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia] |
Search more.